Purpose To investigate the efficacy of spatial and temporal contrast sensitivity (CS) tests for detecting early glaucoma in the presence of cataract
Methods Twenty‐seven early glaucoma patients (mean age 60 ±10.2 years) with early cataractous signs were selected together with twenty‐seven control subjects matched for age and cataract type. Cataracts were graded using the grading scheme of Casser et al (1997). Measurements of grating spatial and temporal CS at 20 HZ in central vision were performed in each group for spatial frequencies (SF) 0.5, 1.5 and 3 c/d with and without glare. Visual acuity, visual fields sensitivity measurements and structural tests using Heidelberg Retina Tomograph (HRT) were also performed.
Results Overall reduction in both spatial and temporal CS at all SF was found for glaucoma patients compared with cataract patients with a significant mean difference of 0.2 log units (p < 0.01). This difference correlated well with measurements of visual fields or and HRT parameters. The effect of the glare on CS was significant (p < 0.01) and was similar for both groups. A significant correlation (p< 0.05) was found between the glare factor and the glaucomatous damage assessed by HRT.
Conclusion Our results indicate that both spatial and temporal CS tests can distinguish glaucomatous vision loss from vision loss resulting from cataracts, the temporal test providing better separation at higher SF. The CS reduction due to the presence of glare increased with the glaucomatous damage, suggesting that there maybe an increase in intraocular straylight in glaucoma. References: 1.Casser L, Fingeret M, and Woodcome T. Atlas of Primary Eyecare Procedures, ed 2, 1997
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.